ArticleFrontiers in pharmacology2022
Beneficial effect of Xuebijing against
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Identifying Baicalein as a Key Bioactive Compound in XueBiJing Targeting KEAP1: Implications for Antioxidant Effects.Antioxidants (Basel, Switzerland) · 2025Article
- The protective effects and mechanisms of rosmarinic acid againstFrontiers in pharmacology · 2025Article
- Transcriptome Analysis Reveals the Mechanism of Y0-C10-HSL on Biofilm Formation and Motility ofPharmaceuticals (Basel, Switzerland) · 2024Article
- The nematodePeerJ · 2024Article
- Antibacterial activity of cinnamon essential oil and its main component of cinnamaldehyde and the underlying mechanism.Frontiers in pharmacology · 2024Article
- Procatechuic acid and protocatechuic aldehyde increase survival ofFrontiers in pharmacology · 2024Article
- Xuebijing improves intestinal microcirculation dysfunction in septic rats by regulating the VEGF-A/PI3K/Akt signaling pathway.World journal of emergency medicine · 2024Article
- Paeoniflorin increases the survival of Pseudomonas aeruginosa infected Caenorhabditis elegans at the immunosuppression stage by activating PMK-1, BAR-1, and EGL-1 signals.Archives of pharmacal research · 2023Article
- Article
- Paeoniflorin mitigates high glucose-induced lifespan reduction by inhibiting insulin signaling inFrontiers in pharmacology · 2023Article
- Treatment with paeoniflorin increases lifespan ofFrontiers in pharmacology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the clinical intensive care units (ICU), the traditional Chinese medicine (TCM) formulation of Xuebijing has been frequently used for treating sepsis. Nevertheless, the underlying pharmacological mechanisms of Xuebijing remain largely unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.